Mission
BioSystems International (BSI) brings biomarkers to the bedside. We improve pharmaceutical drug discovery and development productivity, i.e. safer and more effective drugs at lower costs and in less time. BSI delivers tools for disease management.

Who are we?
BSI merges pharmaceutical and diagnostics industry experience with leading scientific and technology expertise and know-how in bioanalysis, proteomics, genome sciences and immunology. building

What do we deliver?
BSI discovers, rapidly validates and qualifies biomarkers through partnerships with pharmaceutical and biotechnology companies, as well as in focused internal programs

The advantage of BSI's approach
BSI's discovery technology and unique development method combines high throughput monoclonal antibody technology mass spectrometry and genome research technologies. It allows BSI to achieve the targeted quantitative analysis of virtually all proteins in bodily fluids of patients and control subjects with the sensitivity and precision of ELISA assays. BSI builds a streamlined strategy to identify, validate and qualify the most promising biomarkers via a process that includes confirmation of clinical relevance on BSI's patient cohorts or clinical material from large Phase II and Phase III clinical trials of our partners.

Location
The headquarters of BSI is at Genopole in the Paris area in France. BSI operates research laboratories in Evry and at its subsidiary, BSI Kft in Debrecen at the University of Debrecen in Hungary.

Contact:

Mobile: +33 6 72 71 6606
Office: +33 1 60 87 89 31
Fax: +33 1 60 78 71 49
E-mail: laszlo.takacs@biosys-intl.com, info@biosys-intl.com
web: www.biosys-intl.com